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A r ecently d escribed method that enumerates variant 
6-thioguanine resistant peripheral blood lymphocytes 
present in vivo in man as a potential marker of somatic 
cell mutations occurring in vivo was used to study 18 
psoriatic patients receiving PUV A therapy, 16 conven-
tinally treated p soriatic patients, 10 vitiligo patients re-
ceiving PUV A therapy and 7 untreated individuals with 
vitiligo. Variant lymphocyte frequencies determined for 
these individuals were compared with those determined 
for groups of 10 concurrent and 63 cumulative healthy 
control individuals. Variant frequencies were elevated 
in p soriatic and vitiligo patients receiving PUV A ther-
apy and in conventionally-treated psoriatic patients. 
They were not elevated over control values in untreated 
vitiligo patients. 
There is some uncertainty as to what constitutes t he best 
approach to the controlled use of mutagenic agents with the 
potential for human benefit [1-3). Effective medical therapies 
pose a particularly difficult problem in this regard. For this 
reason, the ability to assess genetic damage resulting from such 
agents under the conditions of exposure in terms relevant to 
man is of critical importance. 
It is well establis hed that psoriasis often responds dramati-
cally to photochemotherapy with one of a variety of psoralen 
compounds and long-wave ultraviolet light (PUVA) [4,5). Psor-
alens covalently bind to thymidine in DNA to form monofunc-
tional or bifunctional photoadducts with interstrand crosslinks 
[6-10). Although this activity probably accounts for PUVA's 
effectiveness, it has been suggested that it may also have genetic 
or oncogenic consequences [5). 
Naturally occurring germinal mutations in man of the X-
chromosomal gene for hypoxanthine-guanine phosphorbosyl-
transferase (HG-PRT) give rise to the well characterized Lesch-
Nyhan (LN) Syndrome [31,32]. All somatic cells from LN males 
have the mutant gene, are deficient in HG-PRT, are unable to 
phosphorylate purine analogues and thus are resistant to the 
cytotoxicity of these drugs [22,23). These cells provide proto-
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types at the single cell level for this mutant phenotype. Because 
of random X-chomosomal inactivation, [33,34] some somatic 
cells from pheno-typically normal females heterozygous for the 
LN mutation are also mutant [35,36]. The detection of purine 
analogue resistant cells in heterozygotes provides a model for 
cellular mosaicism for this genetic resistance marker. The nat-
urally occurring LN mutation was used to develop and calibrate 
the system used to detect somatic cell mutants arising in non-
LN individuals in the present studies (21).* 
Earlier, one of us (RJA) had co-developed the human diploid 
fibroblast system, also modeled on the behavior of LN proto-
type mutant cells, to detect environmental agents deleterious 
to the human genetic material in vitro (37). The fibroblast 
system has since been used to define the mutagenicity of several 
environmental agents-including known carcinogens-for hu-
man cells [38,39], has detected the mutagenicity of PUV A when 
applied to human fibroblasts in vitro [15] and has demonstrated 
the extreme sensitivity of fibroblasts from individuals with 
Xeroderma Pigmentosum to ultraviolet light induced mutation 
[40). The rationale for using the purine analogue resistance 
marker for studies of somatic cell mutation is presented else-
where [21,37).· 
We have found that 6-thioguanine resistant (TG') peripheral 
blood lymphocytes (PBL's) are present in low frequencies in 
the blood of healthy, non-LN individuals, and that these fre-
quencies are elevated in groups of cancer patients treated with 
chemotheraputic agents which are known mutagens [21],* In 
the current study we determined the frequency of variant Tar 
PBL's (variant frequency = Vrl for 2 groups of psoriatic pa-
tients-those receiving conventional and those receiving PUV A 
therapy. We did likewise for a group of untreated vitiligo 
patients and for a group receiving PUVA therapy. We compared 
these Vf'S with those determined for healthy controls. We now 
report these results. 
MA TERIALS AND METHODS 
The method of the TG' PBL autoradiographic assay has been 
described in detail [21]. 
Lymphocyte Culture 
Venous blood is collected in a heparinized syringe lBeeflung; Upjohn 
1000 units/ml, 0.1 ml/10 ml blood) and mixed with an equal volume of 
Hank's Balanced Salt Solution (HBSS) containing 0.2% (v:v) heparin 
and 2% (v:v) penicillin/streptomycin mixture (100 units/ ml and 100 p.g/ 
ml respectively; Gibco). Ficoll-Hypaque (2.4 parts of 9% FicoU and I 
part 34% Hypaquel is carefully underlayed, and the mixture centrifuged 
at 600 xg for 30 min. The white blood cell layer is removed, washed 
x2 with supplemented HBSS and resuspended in complete medium 
containing 80 volumes RPMl 1640 with 24 mM Hepes buffer (Microbi-
ological Associates), 0.2% heparin, 2% penicillin/ streptomycin, and 20 
yolumes human AS plasma previously heat-inactivated at 56°C for 20 
• trauss, GH and Albertini RJ . Enumeration of 6-thioguanine re-
sistant blood lymphocytes in man a a potential test for somatic ceU 
mutations arising in vivo. Submitted, Mutation Research, 1979. 
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min and centrifuged at 6000 xg for 10 min. Cell suspensions are made 
to contain 1.1 X 10" cells and 25 ILg reconstituted Bacw-Phytohemag-
glutinin (PHA; Gibco), per ml. 0.1 mJ of TG solution or pH adjusted 
water (control), is added to 0.9 ml of cell suspensions. Triplicate 1 mJ 
cultures are incubated in a humidified 5% CO2 atmosphere at 37°C for 
24 hr in 16 X tOO mJ screw-cap glass point-bottom culture tubes (BeLlco) 
followed by the addition of 1 microcurie 3HTdr (S.A. 2.1; New England 
Nuclear) and an additional 6 hr incubation. 
Autoradiography of Free Nuclei 
The method for preparation of free nuclei is a modification of that of 
Sanford et al [411- At termination of culture, 4 volumes of 0.1 M citric 
acid at 4°C are added to tubes which are centrifuged at 600 xg for 10 
min and the supernatant removed. The pellets are resuspended in 
methanol:acetic acid (5:1) fixative, centrifuged again at 600 xg for 10 
min and the supernatant removed. The pellets are now resuspended in 
0.2 mJ fLXative, left to fLX at 4°C for at least 3 hr, and triturated through 
a 25 gauge spinal needle. The free nuclei in suspension are enumerated 
by counting a 0.025 ml aliquot with an electronic particle counter 
(Coulter Electronics, ZBr Model). The remaining nuclei in suspension 
are carefully added to one of three 18 x 18 mm coverslips which are 
affLXed with Permount (Fisher Scientific) to glass microscope slides. 
Dried slides are stained with 1% aceto-orcein for 2 min and rinsed with 
distilled water. 
To autoradiograph, the dried slides are mechanically dipped into 
NTB-2 (Eastman Kodak) emulsion pre-warmed to 43°C, exposed in 
dark boxes at -70°C for 1-2 weeks, developed in 019 (Eastman Kodak) 
developer at l7°C for 4 min, stopped with a 1 minute exposure to 1% 
acetic acid and fLXed in "hypo" (Eastman Kodak) for 5 min (42). Slides 
are then rinsed in distilled water for 1 min and air-dried. Later studies 
showed that slides could be exposed at -12DC for periods as short as 24 
hr. 
Counting 
Twenty-five hundred nuclei on slides from PHA cultures not con-
taining TG are counted by high-power light microscopy. The incidence 
of autoradiographically labelled cells is determined as the labelling 
index (Ll). All nuclei on slides prepared from PHA stimulated cultures 
containing TG are viewed by low-power (lOOx) microscopy and all 
labeled nuclei on the slides are counted. The LI for TG containing 
cultures is determined from the total number of nuclei on the slides as 
enumerated by the Coulter counter. The Vr is then determined as the 
Ll of PHA stimulated cultures containing TG divided by the Ll of PHA 
stimulated cultures not containing TG as follows: 
Solution.~ 
LI(PHA + TG) -7L-=CI(:=P-=:H:-:-A-:-)~ = Vr 
6-Thioguanine (TG) (2-amino-6-mercaptopurine; Sigma) solution 
was made as a 2 X to 2 M stock, sterilized by passage through a 4 f.l 
filter (Millipore) and added to pH adjusted water in appropriate 
amounts to make test concentrations. Aceto-orcein stain was obtained 
from Gibco. 
Human Subjects 
Healthy individuals of the cumulative control group were obtained 
from laboratory personnel, staff of the Medical Center Hospital of 
Vermont (MCHV) and other volunteers. Patients with psoriasis were 
under the care of the Dermatology Unit, Department of Medicine, 
University of Vermont College of Medicine (PAK) or the Dermatology 
Unit, Hitchcock Clinic and Dartmouth Medical School (RBD) . PUVA 
therapy for patients with psoriasis was given at Hitchcock Clinic, 
Dartmouth Medical School. Blood samples from patients with vitiligo 
were kindly provided hy Dr. David Mosher, Massachusetts General 
Hospital where vitiligo patients received PUVA therapy. Blood samples 
were obtained after receiving informed consent. 
Characteristics of Study Group 
Concurrent controls: This group consisted of 10 healthy individuals, 
(5 women and 5 men) with an average age of 34 yr (range 21-58). 
Psoriatic Patients 
a. Conventional therapy group: Sixteen psoriatic patients (9 women 
and 7 men) with an average age of 55 yr (range 24--86) were undergoing 
conventional therapies consisting of topical steroids (14 patients), mod-
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Hied Goeckerman technique (4 patients), modified Ingram technique 
(2 patients), UVB without tar (3 patients) , and methotrexate (2 pa-
tients). Skin types included I-IV (43); % of body involved varied from 
5-90%. 
b. PUVA therapy group: Eighteen psoriatic patients (5 women, 13 
men) with an average age of 50 yr (range 31-68) were receiving PUV A 
treatments with 8 methoxypsoralen and UVA (total dosage 289 jules/ 
cm" to 4504 jules/cm2). All had received conventional therapy and at 
least 5 of these 18 had had methotrexate at some time in the past. 
Every patient had at least 26 PUV A treatments. Skin types included 1-
IV; % of body involved at time of last treatment varied for 1% to 15%. 
Vitiligo Patients 
Untreated group: Seven vitiligo patients (4 women, 3 men) with an 
average age of 31 yr (range 14-57) were not on treatment. Three of 
these 7 had received psoralen and sun treatment at some time in the 
past. These 7 patients had from 5 to 35% body involvement. 
PUVA therapy group: Ten vitiligo patients (3 women, 7 men) with 
an average age of 27.5 yr (range 4-47) were receiving PUV A treatment 
with 8-methoxypsoralen (4 patients) or trimethoxypsoralen (6 patients) 
and UVA (total dosage 635 joules/em" to 3950 joules/cm"). The number 
of PUV A treatments for this group ranged from 12 to 320. These ten 
patients had from 5 to 70% body involvement. 
Statistical Analysis 
Statistical evaluations of differences in the distributions of V r values 
between groups were made with the Wilcoxon Two Sampl-:l Test. p_ 
values determined in this way were unadjusted. A more conservative 
estimate of the significance of Vr differences among groups when 
compared simultaneously was made with the Kruskal-Wallis test for 6 
populations (cumulative controls, concurrent controls, PUV A treated 
psoriatics, conventionally-treated psoriatics, PUVA treated vitiligo pa-
tients and untreated vitiligo patients) . 
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FIG 1. Frequencies of TG' PBL's (Vr'S) in healthy non-LN individ-
uals shown by age of the individual. The ordinate shows Vr on a 10glO 
scale; the abcissa depicts age by decade. TG' of PBL's was determined 
at 2 x 10 -;J M and 2 X 10- ' M TG. 
Sept. 1979 6-TG RESISTANT PBL'S IN HUMANS FOLLOWING PUVA THERAPY 213 
RESULTS 
PBL V/s in non-LN Healthy Individuals 
TG' PBL frequencies were determined for 83 healthy individ-
uals, some of whom served as concurrent controls for this study. 
In the entire cumulative control groups, 71 experiments in 38 
individuals determined Vr's at 2 X 10- 3 M TG and 98 experi-
ments in 63 individuals determined Vr's at 2 X 10- 4 M TG. 
Eighteen individuals were tested at both TG concentrations. 
The age of individuals ranged from 11 to 75 yr. The median Vr 
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FIG 2. Frequencies of TG' PBL's (Vr'S) of a single healthy non-LN 
individual (ordinate, logl(,) determined over a 2-yr time interval. TG' of 
PBL's was determined at 2 x 10 " and 2 x 10- < M TG. 
when determined at 2 X 10-" M TG was 1.0 X 10- 4 (mean = 1.06 
X 10- ') (10th and 90th percentile = 5 X 10- 5 and 1.5 X 10- 4) 
and, when determined at 2 X 10-4 M TG, was 1.1 X 10- 4 (mean 
= 1.3 X 10- 4) (10th and 90th percentile = 6.1 X 10- 5 and 2.1 X 
10- 4 ). 
Figure 1 gives the results of these experiments with PBL V r's 
arranged according to age of sample donor. The ordinate shows 
Vr's on a 10gJO scale; the abcissa gives age by decade. Each point 
represents one, or the average of several, tests with cells from 
one individual. As can be seen, there is no apparent correlation 
of Vr with age. 
Figure 2 presents the results of multiple tests over a 2-yr time 
interval with PBL's from a single individual. Again, Vr's are 
given on the ordinate (loglO). Twenty-one experiments tested 
cells from this individual at 2 X 10- 3 M TG, while 24 tested cells 
at 2 X 10- ' M TG. At the higher concentration, the range of Vr's 
was 6.2 X 10- 4 to 1 X 10- 5 while at the lower concentration it 
was 2 X 10-' to 3.1 X 10-5. Although the former represents a 60-
fold range, the value of 6.2 X 10- ' is the highest we have ever 
determined in a healthy control, and this on only a single 
occasion. 
PBL V/s in Patients With Psoriasis 
TG' PBL V,-'s were determined at 2 X 10- ' M TG for 16 
psoriatic patients undergoing conventional therapy and 18 pa-
tients receiving PUV A. All PUV A treated patients had received 
at least 26 treatments at the time of the test. 
The Table 1 presents numerical results from a sample exper-
iment. In this experiment, Vr's were determined for a single 
concurrent control individual, and for 3 psoriatic patients re-
ceiving PUV A treatments. The labeling indices ranged from 
0.022 to 0.070 and the psoriatics and controls were not different 
in this regard. The TG' PBL Vr of the control was 9.8 X 10- 5 
while, for the 3 PUV A treated psoriatic patients, the V r's were 
6.4 X lO-a, 7.4 X 10- 4 and 6.7 X 10- 4 • It can be seen that the 
absolute number of TG' variant cells as determined from au-
to radiographically-labeled nuclei in the PHA + TG cultures as 
well as the V/s were elevated for the PUVA treated psoriatics. 
All of the V r values determined in many similar experiments 
with PBL's from psoriatic patients and concurrent controls 
are shown in Fig 3 where V r'S are indicated on the ordinate 
(log 10) and columns represent different groups of individuals. 
The wavy lines represent the median and 10th and 90th per-
centile Vt values determined at 2 X 10- 4 TG for the cumulative 
TABLE I. PBL Vr's Determined at 2 x 10- 4 M TG in Psoriatic Patients Receiving PUVA Therapy 
PHA 
IndIvidual 
LI" Avg. LI 
Normal 
control .040 
.044 .042 
Psoriatic .024 
Patient A .022 
PUV A treaLed .020 
Psoriatic .075 
Patient B .070 
PUV A treated .065 
Psoriatic .058 
Patient C .060 
PUVA treated .062 
• = Labeling index. 
b = Determined by count of entire slide. 
r = Determined by Coulter count of nuclei in suspension. 
J = Variant frequency. 
# labeled 
nuclei/slide6 
2 
2 
73 
81 
21 
27 
33 
27 
Cultures incubated with LI (PHA+TG) PHA + TG 2 x 10 <M 
# nuclei Li(PHA) LI" Avg slide x JOf~ LI = V,TG'" 
3.8 X 10-" .530 4.1 x 10- (; 9.8 X 10 ' 
.470 4.3 X 10-6 
.522 1,4 X 10- 3 
1.4 X 10 3 6.4 X 10-3 
.580 1.4 X 10- 3 
,453 4.6 X 10-5 
5.2 X 10-" 7.4 x 10-' 
.467 5.8 X 10-5 
.765 4.3 X 10-5 
4.0 X 10-' 6.7 x 10- < 
.723 3.7 X 10-' 
V r'S are shown for a single control individual and for 3 PUV A treated psoriatic patients. The labeling index for the control is 0.042; for the 
PUV A treated psoriatic patients the indices are 0.022, 0.070 and 0.060. The TG' PBL V f of the control is 9.8 X 10- 5 and absolute numbers of 
autoradiographically labeled nuclei counted in replicate PHA+TG cultures are 2, and 2. The TG' PBL Vr's of the PUVA treated patients are 6,4 
x 10 J, '1.4 X 10 4 and 6.7 X 10 4 based on absolute autoradiographically labeled nuclei replicate counts of 73,81; 21 , 27 and 33, 27 respectively 
(see methods). 
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FIG 3. Frequencies of TG' PBL's (V's) (ordinate, loglO) are shown 
for psoriatic patients receiving conventional therapy, for psoratic pa-
tients receiving PUVA therapy, for untreated vitiligo patients, for 
vitiligo patients receiving PUVA therapy and for healthy concurrent 
controls. The wavy lines represent the median TG' PBL Vr values of a 
group of 63 healthy individuals tested also at 2 X 10 4 M TG. The 10th 
and 90th percentiles for these control values are presented. Sixteen of 
18 PUV A treated psoriatics, 12 of 16 conventionally treated psoriatics 
and 9 of 10 PUVA treated vitiligo patients have TG' PBL Vr values 
above the 90th percentile of the cumulative control group values. By 
contrast, no concurrent control and no untreated vitiligo patients have 
Vr values greater than the 90th percentile value of the cumulative 
controls. 
control group. Concurrent controls in these experiments served 
as methodological controls. Although quite small, the distribu-
tion of V r's of the concurrent control group does not differ from 
the distribution found in the cumulative control group, of which 
it is a part. By contrast, psoriatic patients receiving PUV A 
treatments present a distribution of V r values which shows 
them to be significantly greater than those of the cumulative 
control group (p < 0.001; Wilcoxon's Two-Sample Test). The 
median Vr of PUV A treated patients is 8.0 x 10- 4 (mean = 1.2 
x 1O-3)(10th and 90th percentile = 5.9 X 10- 5 and 3.5 X 10- 3). 
Likewise, psoriatic patients receiving conventional therapy 
present TG' PBL Vr elevations which are at least as great as 
those that are seen in patients receiving PUV A. For the con-
ventional therapy psoriatic group, the median Vr is 1.8 X 10-3 
(mean = 2.6 X 1O- 3)(10th and 90th percentile = 1.2 X 10-4 and 
7.S X 10- :1). The distribution ofVrvalues is not different between 
this group and the PUV A treated psoriatics while it is signifi-
cantly different between them and the cumulative control group 
(p < 0.001 Wilcoxon's Two-Sample Test) . Even when simulta-
neous group comparisons of Vr values are evaluated, both 
PUVA and conventionally treated psoriatic Vr's are significantly 
elevated over cumulative control group values (p < 0.05). When 
compared with the smaller concurrent control group, conven-
tionally treated psoriatics' Vr elevations over controls are sig-
nificant while those of the PUV A treated group approach 
significance at an alpha level of 0.05. 
PBL Vis in Patients with Vitiligo 
Because of the difficulty of finding untreated psoriatic pa-
tients, a group of individuals was sought who would be either 
Vol. 73, No.3 
untreated or receiving PUVA therapy. Therefore, TG' PBL Vr's 
were determined at 2 X 10-' m TG for 7 untreated and 10 
PUV A treated vitiligo patients. The results of these studies are 
also shown on Fig 3. As can be seen, vitiligo patients receiving 
PUVA therapy have elevated TG' PBL Vr's when compared 
with normals with a median value of 5.1 X 10- 4 (mean = 1.1 X 
1O- :J) (lOth and 90th percentile = 9.6 X 10-5 and 4.2 X 10- 3). The 
Vr values in this group are significantly greater than those of 
the cumulative control group (p < 0.(05) and even approach a 
significant elevation at this alpha level over the small concur-
rent control group. By contrast, for untreated vitiligo patients, 
the group median TG' PBL V r value is only 1.4 X 10- 4 • Seven 
individuals comprise this group, and this small number is in-
sufficient to demonstrate a statistical difference in Vr values 
between them and the PUV A treated vitiligo group. However, 
9 of the 10 Vr values for PUV A treated vitiligo patients are 
greater than any in the non-PUV A treated group. All V r values 
for the non treated vitiligo group fall with the 10th and 90th 
percentile for the Vr values of the cumulative control group 
while 9 of the 10 V r values for PUV A treated vitiligo patients 
are above the 90th percentile for cumulative controls. 
DISCUSSION 
We have shown both here and elsewhere that TG' PBL's 
occur in normal individuals at low frequencies which are ele-
vated in persons exposed to putative mutagens. The TG resist-
ant phenotype of these cells resembles that of LN PBL's where 
an X-chromosomal gene mutation results in deficiency of the 
enzyme hypoxanthine-guanine phol'phoribosyltransferase (HG-
PRT)[22,23,31,32]. This enzyme activity is necessary to 
phosphorylate purine analogues and render them cytotoxic 
[26-30]. A similar resistance, which is also associated with HG-
PRT deficiency, can be induced in normal fibroblast exposed in 
vitro to mutagens [37], This resistant phenotype is heritable 
over the somatic line in fibroblasts and is assumed to result 
from a process akin to mutation. The fibroblast system has 
been used to detect agents which damage the human genetic 
material [15,38-40]. 
Although we do not know the nature of TG' PBL's in non-
LN individuals, it seems reasonable to assume that at least 
some of them also result from somatic cell mutation. Further-
more, the X-chromosomal location of the gene for HG-PRT 
makes mutation at this locus an appealing explanation for TG 
resistance because expression of the resistant phenotype should 
follow directly from mutation. The observed frequencies ofTG' 
PBL's are consistent with mutation at a hemizygous locus. In 
this regard, it is of note that we were unable to fmd 2, 6-
dian ' lIopurine resistant (DAP') PBL's in 2 individuals in an-
other sL"dy even though the frequency of TG' PBL's was 
greatly elevated in one. This, too, is consistent with the muta-
tion hypothesis since adenine phosphoribosyltransferase 
(APRT), which is required to phosphorylate DAP, is specified 
by an autosomal gene (chrol,10some 16) [44]. 
Purine analogue resistanc. in mammalian cells may, of 
course, be due to factors oth' than HG-PRT deficiency [45, 
46]. Mutation or other alterab" IS at several sites may give rise 
to TG' PBL's and current studies are underway to better define 
the nature of these cells. However, the reasons for resistance 
may not be strictly relevant to environmental mutagenesis 
studies if TG' PBL Vr changes correlate with known mutagen 
or carcinogen exposures. This correlation has been suggested 
for cancer patients receiving cytotoxic agents which possess a 
known capacity to damage the genetic material [21] -, 
In the current study, TG' PBL V r's in the small group of 
concurrent control individuals did not differ from those deter-
mined over approximately a 2-yr interval for a much larger 
group of healthy individuals. Psoriatic patients, however, pre-
sented definite elevations in the frequencies of these variant 
cells. These Vr elevations did not depend on whether or not the 
psoriatic patient was receiving PUV A treatments. By contrast, 
although TG' PBL Vr's in vitiligo patients receiving PUV A 
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treatments were elevated over controls, the V,'s in untreated 
vitiligo patients did not differ from those of normal individuals. 
The finding of elevated TG' PBL V,'s in psoratic patients 
receiving PUV A treatments is not unexpected. The human 
diploid fibroblast system, which assays the same indicator of 
mutation, is one of the several systems which have shown 
PUV A to be mutagenk in vitro [15]. Since expo ure of all 
lymphocytes in the peripheral blood of man coulo theoretically 
be achieved with an 11 min exposure to UV A [18], there is 
ample opportunity for lymphocytes in vivo to receive doses 
similar to those given to the fibroblasts. That the treated 
psoriatic and treated vitiligo patient groups both showed ele-
vations of TG' PBL V,'s suggests that the PUVA itself is 
responsible. 
Psoriatic patients receiving conventional therapy also showed 
elevations of TG' PBL V,'s and did not differ from the PUVA-
treated group in this regard. All conventionally-treated psoriatic 
patients had severe psoriasis. 
This finding raises the possibility that the psoriatic process 
itself may result in an increased frequency of TG' variant 
lymphocytes. It is known that immunological stimuli are mu-
tagenic to mammalian cells (47,48). In fact, lymphoid cells may 
be highly mutable, and this characteristic may be intrinsic to 
their normal functions [49J and, conversely, may result in a 
variety of benign and malignant disorders. Immunological 
mechanisms have been implicated in the pathogenesis of pso-
riasis [50). If the psoriatic process itself, for any reason, results 
in elevated TG' PBL V,'s, elevations should be seen also in 
patients not receiving therapy. Studies of untreated individuals 
with psoriasis are currently in progress. 
An alternative possibility exists that some of the therapies 
employed in the non-PUV A treated psoriatics were themselves 
mutagenic. Genetic damage to somatic cells could then have 
resulted if adequate exposure to target ceUs was achieved. 
Further investigations are required to evaluate this possibility. 
The finding of elevated TG' PBL Vr's in humans receiving 
PUV A treatments is not at variance with the finding that sister 
chromatid exchanges (SCE's) are not elevated in PBL's of these 
patients under conditions of clinical PUV A use (19]. SCE's may 
measure a different kind of genetic damage. Also, because 
SeE's could be induced by PUVA in vitro, it is possible that 
genetic damage occurring in vivo does not persist long enough 
to demonstrate SCE's in vitro. Furthermore, there may be 
selection in vivo against damaged cells. Elsewhere, we have 
presented evidence that there is, in fact, selection in vivo against 
the LN TG' PBL's [21).* Since TG' PBL V,'s in normal indi-
viduals are not age-related, there also is apparent in vivo 
selection against the non-LN variety of this cell. Nonetheless, 
recovery of TG' PBL's resulting from gene mutations may be 
greater than is the recovery of cells that have experienced the 
sort of genetic event that allows the demonstration of SCE's. 
The current study employs an assay directed towards detect-
ing somatic cell mutations occurring in vivo in man. Mutagen-
esis studies using the several available systems to test isolated 
agents in vitro are important as initial screening tests to identify 
putative mutagens [1]. However, some agents so identified may 
have benefits that cannot easily be rejected. In this regard in 
vivo studies have several important features. They may allow 
an assessment of the genetic effects of these agents under actual 
conditions of use. They may be used to determine the genetic 
effects of exposures to specific agents in combination with 
others. Also, in vivo studies are required to assess the impor-
tance of pharmacokinetic and metabolic factors that influence 
the delivery of genetically active agents to genetic targets [IJ. 
Finally, unique individual susceptibilities to genetic damage or 
the influence of disease in producing such damage may be 
detected by in vivo studies. 
The current study suggests the need for longitudinal deter-
minations of TG' PBL V r's in psoriatic patients and others 
receiving PUV A treatments as well as in psoriatic patients 
receiving conventional therapies. These are underway. Also, 
TG' PBL V,'s are being determined in patients with psoriasis 
who are not on therapy. Our findings to date in PUVA-treated 
humans are con istent with findings from several sources that 
suggest that this treatment produces genetic damage. We report 
them now because of their intrinsic importance, and to present 
the TG' PBL autoradiographic assay for consideration as a 
potential monitoring system to detect somatic ceU mutations 
occurring in vivo in man. 
We thank Dr. Taka Ashikaga for helpful suggestions regarding 
statistical analysis of the data. 
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Announcement 
The National Institute on Aging invites applications for research grant support in gerontological and 
geriatric dermatology. Skin problems of the aging and elderly contribute markedly to decline in quality 
of life. Neither the basc mechanisms responsible for age-associated changes in skin, nor the m eans for 
intervention, treatment and/or prevention of the associated problems are adequately understood. Re-
search is necessary at the molecular, cellular and clinical levels. The traditional NIH research grant 
meqhanism and procedures are available to applicants. Application receipt dates for project grants are 
November 1, March I, and July 1. 
Inquiries are welcome. Potential applicants should notify the NIA with a letter of intent. Address 
correspondence to: Basic Aging Program-Dermatology, Biomedical Research and Clinical Medicine, 
Building 31, Room 5C21, National Institute on Aging, NIH, Bethesda, Maryland 20205. 
